You have no items in your shopping cart.
You have no items in your shopping cart.
Catalog Number | orb1806343 |
---|---|
Category | Antibodies |
Description | Anti-ERBB2 / HER2 / CD340 Reference Antibody is expressed from CHO. It has a predicted MW of 145.5 kDa. |
Target | ERBB2 / HER2 / CD340 |
Clonality | Monoclonal |
Conjugation | Unconjugated |
Reactivity | Human, Mouse |
Concentration | 1 mg/mL |
Buffer/Preservatives | 100 mM Proline/Acetic acid 20mM Arginine pH 5.0 |
Purity | >95% |
Purification | Protein A |
UniProt ID | P04626 |
MW | 145.36 kDa |
Tested applications | ELISA, FA, FACS, In vivo |
Expression System | CHO |
Endotoxins | <0.001 EU/ug |
Storage | Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles. |
Note | For research use only |
Expiration Date | 12 months from date of receipt. |
Anti-ERBB2 / HER2 / CD340 Reference Antibody (trastuzumab) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.
The purity of Anti-ERBB2 / HER2 / CD340 Reference Antibody (trastuzumab)is more than 95% ;determined by SEC-HPLC.
Immobilized human HER2; His at 2 μg/mL can bind Anti-ERBB2 / HER2 / CD340 Reference Antibody (trastuzumab);EC50=0.005735μg/mL.
BT474 cells were stained with Anti-ERBB2 / HER2 / CD340 Reference Antibody (trastuzumab) and negative control protein respectively; washed and then followed by PE and analyzed with FACS; EC175=0.3024 μg/mL.
Trastuzumab inhibited the tumor growth of BT474 on NCG mice. The result showed significant anti-tumor effects; with an tumor inhibition rate (TGI) of 88.5% at 10 mpk at D35.
ELISA, FC | |
Human, Mouse | |
Monoclonal | |
Unconjugated |
ELISA, FC | |
Human, Mouse, Rat | |
Monoclonal | |
Unconjugated |
ELISA, FA, FACS, In vivo | |
Human, Monkey, Mouse | |
Monoclonal | |
Unconjugated |
ELISA, FC | |
Human, Monkey, Mouse, Rat | |
Monoclonal | |
Unconjugated |
ELISA, FC | |
Human | |
Monoclonal | |
Unconjugated |